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Introduction: Hypercoagulability in malignancy increases the risk of thrombosis, but is also involved in cancer
progression. Experimental studies suggest that tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are
involved in cancer biology as a tumor- promoter and suppressor, respectively, but the clinical significance is less
clear. Here, we aimed to investigate the clinical relevance of TF and TFPI genetic and phenotypic diversity in breast
cancer.
Methods: The relationship between tumor messenger RNA (mRNA) expression and plasma levels of TF and TFPI
(α and β), tagging single nucleotide polymorphisms (tagSNPs) in F3 (TF) (n = 6) and TFPI (n = 18), and clinicopathological
characteristics and molecular tumor subtypes were explored in 152 treatment naive breast cancer patients. The effect
of tumor expressed TF and TFPIα and TFPIβ on survival was investigated in a merged breast cancer dataset of 1881
patients.
Results: Progesterone receptor negative patients had higher mRNA expression of total TFPI (α + β) (P = 0.021) and
TFPIβ (P = 0.014) in tumors. TF mRNA expression was decreased in grade 3 tumors (P = 0.003). In plasma, total TFPI
levels were decreased in patients with larger tumors (P = 0.013). SNP haplotypes of TFPI, but not TF, were associated
with specific clinicopathological characteristics like tumor size (odds ratio (OR) 3.14, P = 0.004), triple negativity (OR 2.4,
P = 0.004), lymph node spread (OR 3.34, P = 0.006), and basal-like (OR 2.3, P = 0.011) and luminal B (OR 3.5, P = 0.005)
molecular tumor subtypes. Increased expression levels of TFPIα and TFPIβ in breast tumors were associated with better
outcome in all tumor subtypes combined (P = 0.007 and P = 0.005) and in multiple subgroups, including lymph node
positive subjects (P = 0.006 and P = 0.034).
Conclusions: This study indicates that genetic and phenotypic variation of both TFPIα and TFPIβ, more than TF, are
markers of cancer progression. Together with the previously demonstrated tumor suppressor effects of TFPI, the
beneficial effect of tumor expressed TFPI on survival, renders TFPI as a potential anticancer agent, and the clinical
significance of TFPI in cancer deserves further investigation.* Correspondence: nina.iversen@medisin.uio.no
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There is now convincing evidence of a relationship be-
tween cancer and hemostasis. An oncogene driven
thrombophilic environment frequently arises in cancer
and involves the capacity of tumor- and stimulated host
stroma cells to express and release clotting factors, inflam-
matory cytokines, proangiogenic factors, and procoagulant
microparticles (MPs) [1]. One obvious manifestation of
cancer-associated coagulopathy is the increased risk of
venous thrombosis (VT) among cancer patients [2-4],
however, the procoagulant state may also promote tumor
progression [5]. Full-length tissue factor (TF) [GenBank:
NM_001993] is the most extensively studied coagulation
factor in cancer, and its activity is regulated by TF pathway
inhibitor (TFPI). Expression of both TF and TFPI has been
detected in tissues and cell lines of several human can-
cers including breast cancer [6-10], suggesting a role in
cancer biology. TF is known to be a trigger of angiogen-
esis, proliferation, migration, and invasion, and to pre-
vent apoptosis [11-14]. These effects may either be
coagulation dependent, indirectly through fibrin forma-
tion and platelet activation, or through coagulation inde-
pendent signaling via factor VIIa (FVIIa) and activation
of protease activated receptor 2 (PAR-2), enhanced by β1
integrin [5,12].
Full-length TFPI (TFPIα) [GenBank: NM_006287] con-
sists of three Kunitz-type inhibitor domains and a posi-
tively charged carboxy-terminal (C-terminal) end, while
the alternatively spliced TFPIβ [GenBank: NM_001032281]
lacks the third Kunitz domain and has a unique C-terminal
that directs binding to a glycosylphosphatidylinisotol
(GPI) anchor on the cell surface [15]. There is growing
evidence for non-hemostatic tumor-suppressive activities
of TFPI. Studies of endothelial cell cultures have shown
that recombinant TFPIα induces apoptosis [16], inhibits
proliferation via the very low density lipoprotein recep-
tor [17], and show anti-angiogenic and anti-migratory
properties [18,19]. In addition, manipulation of their ex-
pression revealed that both the TFPIα and the TFPIβ
isoform have tumor-suppressive features in breast can-
cer cells, similar to that observed in endothelial cells
[20,21]. Supporting the in vitro observations, in vivo
studies have demonstrated that both circulating recom-
binant TFPI and TFPI-expressing tumor cells sig-
nificantly attenuated tumor growth [13,22] and lung
metastasis in mice [13,23]. A transgenic murine model
of TFPI overexpression suggested that the C-terminal
end of TFPIα caused impaired angiogenesis by inhibition
of phosphorylation of vascular endothelial growth
factor receptor 2 [19]. A few TFPI and TF (F3) single
nucleotide polymorphisms (SNPs) have been reported
and assigned a possible, but not definite role in
modifying transcription or plasma levels of TFPI and
TF [24-30].Breast cancer is a highly heterogeneous disease and
several subgroups exist that differ in prognosis and man-
agement options. Three main tumor subtypes may be
determined using traditional immunohistochemistry (IHC);
hormone receptor (HR) positive (i.e., estrogen receptor
(ER) and progesterone receptor (PR) positive), human epi-
dermal growth factor receptor 2 (HER2) positive, and
triple negative tumors. In addition, whole-genome gene
expression profiling has enabled categorization of tumors
into the intrinsic molecular subtypes luminal A, luminal
B, HER2-enriched, basal-like and normal-like [31].
In the present study, we aimed to investigate the clinical
relevance of TFPI and TF in breast cancer. The inter-
relationships between TFPI and TF tagSNPs, tumor
mRNA expression and plasma levels, and their association
with breast cancer subtypes and survival were explored in
either 152 treatment naive breast cancer patients or a
merged 1881-sample breast tumor data set.
Materials and methods
Case subjects
The study comprised 152 primary operable (cT1-cT2) fe-
male breast cancer patients (Table 1) enrolled between
June 2008 and August 2010 at the Oslo University Hos-
pital Ullevål, Oslo, and the Akershus University Hospital,
Nordbyhagen, Norway. All subjects were of Scandinavian
descent (mainly Norwegian, some Swedish or Danish).
The cases were included at the time of primary surgery
(mastectomy or lumpectomy), without receiving any pre-
operative treatment. Blood samples were drawn immedi-
ately before surgery and tumor tissue was fresh frozen in
liquid nitrogen and stored at −80°C after macroscopic
evaluation of the surgical specimen by an experienced
breast pathologist. None of the subjects were pregnant or
received any anticoagulant- or hormone replacement ther-
apy. The age average at the time of surgery and blood
sampling was 56.0 (standard deviation (SD) 12.4) years.
The Norwegian southeastern Regional Committee for
Medical and Health Research Ethics approved the study
protocols (approval number 1.2006.1607, amendment
1.2007.1125 for Ullevål patients and 429–04148 for Aker-
shus patients) and all included women gave their written
informed consent to participate.
Clinicopathological characteristics
Clinicopathological data were retrieved from pathology
reviews, and the following clinicopathological character-
istics were included in the study; tumor size (T-status),
lymph node (N) status, tumor grade (well/moderately/
poorly differentiated), ER status, PR status, and HER2
status (Table 1). T-status, N-status and tumor grade was
specified according to national (NBCG, [32] guidelines
and World Health Organization (WHO) recommenda-
tions. ER and PR status of the tumors were determined
Table 1 Clinicopathological characteristics of the 152 breast
cancer patients
Characteristic Number (%)
Gender
Female 152 (100)
Male 0 (0)
Age
<_55 80 (52.6)
>55 72 (47.4)
Mean (±SD) 56.0 (12.4)
Tumor size (T-status)
T1 (0–20 mm) 77 (50.7)
T2 (20–50 mm) 68 (44.7)
T3 (>50 mm) 7 (4.6)
(T2-T3) (75 (49.3))
Grade
G1 (well differentiated) 21 (13.8)
G2 (moderately differentiated) 53 (34.9)
(G1-G2) (74 (48.7))
G3 (poorly differentiated) 78 (51.3)
Estrogen receptor (ER) status
Negative 35 (23.0)
Positive 117 (77.0)
Progesterone receptor (PR) status
Negative 51 (33.6)
Positive 101 (66.4)
Human epidermal growth factor receptor 2 (HER2) status
Negative 137 (90.1)
Positive 15 (9.9)
Hormone receptor (HR) negative status (ER/PR negative)
Yes 34 (22.4)
No 118 (77.6)
Triple negative (TN) status (ER/PR/HER2 negative)
Yes 29 (19.1)
No 123 (80.9)
Lymph node (N) status
N0 (0 lymph nodes) 98 (64.5)
N1 (1–3 lymph nodes) 40 (26.3)
N2 (4–9 lymph nodes) 11 (7.2)
N3 (>_10 lymph nodes) 3 (2.0)
(N1-N2-N3)a (54 (35.5))
Molecular tumor subtypes (PAM50 signatures)
Basal 25 (16.7)
HER2 enriched 15 (10.0)
Table 1 Clinicopathological characteristics of the 152 breast
cancer patients (Continued)
Luminal A 63 (42.0)
Luminal B 39 (26.0)
Normal-like 8 (5.3)
aLymph node positive group.
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pathology guidelines. HER2 status was determined by
IHC and/or by silver enhancement in situ hybridization
(SISH) (Roche, Dual SISH HER-2) where a HER2 gene/
centrosome 17 (CEP17) ratio of > 2.2 defined HER2
positivity.
Tumor preparation
Tumor tissue from each patient was cut into three
pieces and two frozen sections were taken, Hematoxylin
and Eosin (HE) stained, and evaluated for the presence
of tumor cells. Afterwards, the three tumor pieces were
combined and cut into small pieces. DNA and RNA iso-
lation were thereafter performed from the mixed tumor
tissue.
RNA isolation and TFPI and TF mRNA expression in tumor
Total RNA was isolated from the breast tumors with
Trizol and quality controlled using the Agilent 2100
Bioanalyzer. 100 ng total RNA was applied to the Sure-
Print G3 Human GE 8x60K one-color microarrays (Agilent
Technologies, Santa Clara, CA, USA). Scanning was per-
formed with Agilent Scanner G2565A, using Agi-
lentG3_GX_1Color as profile. Signals were extracted
using FE v.10.7.3.1 and protocol GE1_107_Sep09 (Agilent
Technologies). Probe-values were log2-transformed, and
samples were quantile normalized and hospital-adjusted
by subtracting from each probe value the median probe
value among samples from the same hospital. In the
present study, only expression ratio results obtained with
TFPI and TF (F3) probes were used for further analysis
(Additional file 1: Table S1). The three TFPI probes
present on the microarray were specific for 1) the TFPIα
isoform, 2) the TFPIβ isoform, and 3) total TFPI expres-
sion (TFPIα + TFPIβ). Four SNPs were observed in these
probe regions (TFPI rs79927400, TFPI rs187580582, TF
rs3917635, and TF rs191529173), however, according to
the 1000 genome project [33] all were low frequent with a
minor allele frequency (MAF) ≤1%. A deletion
(rs71653267) in the TF probe has been reported (dbSNP
build 138), however, with unknown significance and fre-
quency. No repetitive DNA elements were found within
any of the probe regions.
The microarray data have been submitted to the Gene
Expression Omnibus (GEO) database with accession
number GSE58215.
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The prediction analysis of microarray 50 (PAM50) sub-
type algorithm described by Parker et al. [34] was used
to assign a subtype label to each sample. In short, a
combined centroid was defined as a weighted average of
the centroids for ER-negative and ER-positive samples,
and each sample was centered by aligning the combined
centroid with the centroid of the training data set pro-
vided in [34], achieved by subtracting the combined cen-
troid from the expression vector of each sample and
then adding the centroid of the training data set. Sub-
type labels (luminal A, luminal B, basal, HER2 enriched,
and normal-like) were assigned by calculating the Spear-
man correlation between the expression vector of each
individual sample and each of the five PAM50 centroids.
The subtype with the highest correlation was selected.
DNA isolation from whole-blood and tumor material
DNA from whole blood was either isolated on the
BioRobot Universal with the QIAamp DNA Blood
BioRobot MDx Kit (Qiagen, Hilden, Germany) and eluted
in Qiagen buffer AE (10 mM Tris-Cl 0.5 mM EDTA;
pH 9.0), or with the Gentra Autopure LS machine using
the Puregene Genomic DNA purification Kit (Gentra Sys-
tems, Minneapolis, MN 55441 USA), or manually using
the MasterPure TM DNA Purification Kit for Blood
Version II (Epicentre® Biotechnologies, Madison, WI, USA).
Fresh frozen tumor tissue was cut with scalpel, and
one piece was used for DNA isolation using the Max-
well® 16 instrument (Promega, Madison, WI, USA) and the
Maxwell® 16 tissue DNA Purification Kit (Promega). DNA
was isolated according to the manufacturer’s protocol. The
isolation procedure is automated, starting with sample lysis
and tissue homogenization, followed by bead isolation of
DNA, and finally the washing steps. The DNA was eluted in
TE buffer (pH 8.5). DNA was stored at −20°C. DNA con-
centration and quality were measured using NanoDrop®
ND-1000 (NanoDrop Technologies, Wilmington, DE, USA).
SNP selection, genotyping, and quality control
SNPs in the TFPI and TF gene regions were selected
using a SNP tagging approach. The tagSNP selection
was performed using the Tagger program [35] imple-
mented in Haploview v. 4.2. and genotype data from the
Caucasian population (Utah residents with ancestry from
Northern and Western Europe) from the HapMap pro-
ject release 27, phase III on NCBI B36 assembly,
dbSNPb126. Using a MAF criterion of ≥5% and pairwise
r2 ≥ 0.8 as a cut-off for proxies, sixteen tagSNPs in the
TFPI gene and four tagSNPs in the TF gene were se-
lected for genotyping. In addition, three SNPs in TFPI
(rs5940, rs10931292 and rs10176633) and two SNPs in
TF (rs958587 and rs3917643) with a previously sug-
gested expression regulatory function were included.Thus the final SNP selection consisted of nineteen TFPI
SNPs and six TF SNPs. However, one of the TFPI SNPs
failed to design (rs8176500), leaving eighteen TFPI SNPs
for genotyping.
Germline SNPs were genotyped in whole blood (four-
teen TFPI SNPs and six TF SNPs) or tumor tissue (four
TFPI SNPs) using the iPLEX Gold massarray platform
(Sequenom) at the Centre for Integrative Genetics,
Norwegian University of Life Sciences, Ås, Norway, or
the Affymetrix® Genome-Wide Human SNP Array 6.0 at
AROS Applied Biotechnology AS, Aarhus, Denmark, re-
spectively. Due to the tumor genome being prone to
mutational and copy number changes, including loss of
heterozygosity (LOH), the tumor-derived SNP genotypes
may occasionally deviate from the germline genotypes.
Therefore, the tumor-derived SNP data were processed
to deduce germline SNPs. With access to blood-derived
germline genotype data for all patients on a set of 22
SNPs (rs8176548, rs3917615, rs696619, rs2227607,
rs2227589, rs12488200, rs9332542, rs9332618, rs6012,
rs4524, rs491098, rs421766, rs4149762, rs4149674,
rs473598, rs3211752, rs2227426, rs2070022, rs153311,
rs2227750, rs37246, rs2070852) present on the Human
SNP Array 6.0, we verified a convergence of 93.8% be-
tween the deduced germline SNPs (from tumor) and the
true germline SNPs (from blood). Due to this fairly high
genotype agreement, we concluded that the tumor-
derived SNPs included in this study (n = 4, indicated in
Additional file 2: Table S2) could be considered as germ-
line SNPs.
All SNPs were in Hardy-Weinberg equilibrium (signifi-
cance threshold P < 0.001). Genotyping was successful for
≥50% of the SNPs in all individuals. Three TFPI SNPs had
genotyping call rates <97% (rs2041778, rs10931292 and
rs8176508), and one TFPI SNP was monomorphic
(rs10176633). After removal of these four SNPs, fourteen
TFPI SNPs (Additional file 2: Table S2 and Additional file
3: Figure S1) and six TF SNPs (Additional file 2: Table S2)
remained for further analysis.
Blood sampling and TFPI/TF protein levels in plasma
Venous blood samples were collected in Vacutainer® vac-
uum tubes (Becton-Dickinson, Plymouth, UK) contain-
ing 0.5 mL buffered sodium citrate (0.129 mol/L).
Whole blood was centrifuged for 15 min at 2000 g at
room temperature within 1 hour to prepare platelet poor
plasma, and aliquots were stored at −70°C until ana-
lyzed. TFPI protein levels in plasma were determined
using the commercial Free and Total TFPI ELISA kits
(Asserachrom®, Diagnostica Stago, Asnière, France),
while the Zymutest Tissue Factor full-length (RK035A,
Hyphen BioMed, Neuville-Sur-Oise, France) was used to
measure TF protein. The manufacturers’ recommended
protocols were followed.
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Statistical analyzes were performed using SPSS (version
21.0; SPSS Inc., Chicago, IL, USA), PLINK v.1.07 [36], and
R 3.1.0 [37]. Associations between continuous-valued ex-
pression levels were assessed with Pearson correlation or
Spearman rank correlation. The relation between SNP ge-
notypes and expression levels was investigated by linear re-
gression. Genotypes were treated as ordinal variables (0, 1
or 2 copies of the minor allele), thus assuming potential
allele-dosage effects to be linear. Regression coefficients are
denoted B and the correlation coefficients are denoted r.
For associations between expression levels and clinico-
pathological characteristics, heatmaps were constructed
in R. Missing value imputation of the gene expression
data was performed with LSimpute [38] using the row
mean method. Two-group comparisons of expression
levels were performed using the t-test or the Mann–
Whitney U test as appropriate. One-way ANOVA or
Kruskal-Wallis test was used for multi-group compari-
sons. Associations between SNPs and binary clinicopath-
ological characteristics were examined using logistic
regression under the additive risk model, with the clini-
copathological variable(s) as the dependent variable and
genotype(s) (coded 0, 1, 2 for each extra risk allele) as
the categorical independent variable. Risk alleles were
defined as the alleles being more prevalent among the
non-reference category, thus consequently obtaining
positive odds ratios (ORs >1). ORs with corresponding
95% confidence intervals (CIs) were reported.
Independence between SNPs was tested by conditional
analysis in PLINK, where the allelic dosage for a given
SNP was added as a covariate in a logistic regression
model. Pairwise SNP dependencies exist if individual ef-
fects disappear when conditioned on the other SNP. The
expectation–maximization (EM) algorithm was used to
estimate haplotype frequencies, and haplotype-based asso-
ciation analysis was conducted using logistic regression
(additive model) for associations with clinicopathological
variables and linear regression for associations with ex-
pression levels. Haploview v. 4.2 was used for creating
linkage disequilibrium (LD) plots. False discovery rate
(FDR, [39]) was used to account for multiple testing, and
tests with P < 0.05 and FDR < 0.20 were reported.
Bioinformatic analysis using the Gene expression based
Outcome for Breast cancer Online (GOBO) database
The GOBO database is a web-based tool that enables a
variety of analyzes of gene expression data in a merged
1881-sample breast tumor data set of 11 different pub-
licly available datasets, all generated on Affymetrix
U133A microarrays [40]. Four TFPI specific probe sets
(one for total TFPI (α + β), two for TFPIα, one for
TFPIβ) and one probe set for TF gene expression were
identified (Additional file 4: Table S3).Using the Gene Set Analysis application, the TFPI and
TF gene expressions were dichotomized to levels above
the median (high expression) or below the median (low
expression) before Kaplan-Meier plots were created and
univariate analyzes (log-rank) were performed to predict
10-year censored overall and relapse free survival. This
was conducted in the complete 1881-sample merged
clinical data set (hereafter termed “all tumors”) as well
as in clinical subgroups. Multivariate Cox proportional
hazards regression analyzes were carried out to account
for possible survival effects of the following covariates;
tumor size, age, histological tumor grade, lymph node
status and ER-status. In addition, GOBO was used to as-
sess the distribution of TFPI and TF gene expressions
across clinical subgroups.
Results
TFPI and TF expression in breast cancer subtypes
First, we investigated the clinical relevance of TFPI or
TF mRNA expression in breast tumors and TFPI or TF
plasma concentrations. Patients were stratified according
to clinicopathological tumor characteristics as defined in
Table 2, with median expression levels for each group.
Significant differences in mRNA expression or protein
levels are illustrated by heatmaps (Additional file 5:
Figure S2). TFPI or TF mRNA expression in breast tu-
mors and plasma concentrations were then compared
between the five molecular tumor subtypes (Figures 1
and 2, respectively).
Total TFPI (α + β) mRNA expression was increased in
patients with PR-negative tumors (P = 0.021), and in pa-
tients with HER2-positive tumors, larger tumor sizes,
and positive lymph nodes, although power was lacking
to achieve statistical significance. Expression of the
TFPIα isoform was higher in PR-negative and HER2-
positive patients, whereas TFPIβ was significantly higher
only in PR-negative patients (P = 0.014). No differences
in TFPI mRNA expression were observed between the
stratified groups for grade, ER status, HR status, or
triple-negative status (Table 2). Moreover, total TFPI
(α + β), TFPIα and TFPIβ expression levels were differen-
tially distributed among the five molecular breast cancer
subtypes; with higher expression in the HER2-enriched
and the normal-like group, and lower in luminal B tumors
(Figure 1A). These observations were mainly supported by
equivalent analyses of the merged breast cancer dataset in
GOBO (Additional file 6: Figure S3).
TF mRNA expression was significantly decreased in
patients with grade-3 tumors compared with patients
with grade 1 or 2 (P = 0.003) (Table 2), and this was vali-
dated by gene expression pattern analysis of the merged
breast cancer dataset (Additional file 7: Figure S4).
When stratified by molecular subtypes, TF mRNA ex-
pression was higher in luminal A and the normal-like
Table 2 TFPI and TF tumor mRNA expression across clinicopathological breast cancer subtypes
mRNA expression (tumor) Protein levels (plasma)
Characteristic Groups Total TFPI
(α + β)
P TFPIα P TFPIβ P TF P Total
TFPI
P Free
TFPI
P TF P
T-status T1 −0.146 0.054 −0.135 0.257 −0.084 0.201 −0.023 0.652 72.01 0.013 10.82 0.997 4.14 0.125
T2-T3 0.085 0.018 0.060 0.054 65.02 10.82 4.66
Grade G1-G2 −0.022 0.850 −0.005 0.424 −0.033 0.743 0.271 0.003 71.04 0.082 10.66 0.682 4.63 0.557
G3 −0.045 −0.113 0.004 −0.229 66.12 10.97 4.14
N-status Negative −0.109 0.091 −0.136 0.127 −0.082 0.104 0.005 0.881 69.93 0.183 10.77 0.869 4.95 0.282
Positive 0.104 0.078 0.110 0.032 66.00 10.90 4.14
ER status Positive −0.067 0.317 −0.082 0.557 −0.056 0.183 0.001 0.784 69.42 0.240 10.91 0.671 4.42 0.409
PR status Negative 0.076 0.011 0.123 0.057 65.44 10.52 5.28
Positive −0.131 0.021 −0.145 0.075 −0.112 0.014 0.085 0.244 69.81 0.195 11.19 0.175 4.32 0.246
HER2-status Negative 0.161 0.108 0.182 −0.127 65.92 10.08 5.04
Negative −0.072 0.054 −0.101 0.073 −0.041 0.154 0.004 0.731 68.45 0.893 10.68 0.287 4.47 0.428
Positive 0.313 0.301 0.228 0.103 69.09 12.05 4.78
HR status Yes 0.076 0.326 0.007 0.587 0.114 0.221 0.016 0.991 64.78 0.161 10.41 0.568 5.26 0.470
No −0.066 −0.080 −0.052 0.014 69.57 10.94 4.47
Triple-negative status Yes −0.051 0.886 −0.110 0.718 0.041 0.635 −0.158 0.326 63.21 0.072 10.06 0.345 5.23 0.969
No −0.029 −0.048 −0.027 0.055 69.73 10.99 4.57
Median values for TFPI and TF mRNA expression in tumors and protein levels in plasma according to clinically defined groups. Corresponding P-values
(unadjusted) are shown. Significant P-values in bold. TFPI, tissue factor pathway inhibitor; TF, tissue factor; HER2, human epidermal growth factor receptor 2.
Abbreviations: T, tumor; G, grade; N, node; ER, estrogen receptor; PR, progesterone receptor; HR, hormone receptor.
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Similar results were obtained using the merged breast
cancer dataset (Additional file 6: Figure S3).
In plasma, antigen levels of free TFPI and TF were
similar between all stratified clinical groups, whereas
total TFPI was decreased in patients with larger tumors
(P = 0.013), and patients with grade-3 or triple-negative
tumors (not significant) (Table 2). Total TFPI or free
TFPI (Figure 2A), and TF plasma levels (Figure 2B) were
not significantly different across molecular subtypes.
As expected, the total TFPI (α + β), TFPIα and TFPIβ
mRNA expression levels in breast tumors were highly
correlated (r = 0.82 to 0.91, P <0.001), and did also correl-
ate significantly to TF expression (r = 0.37-0.50, P <0.001).
In plasma, total TFPI protein levels correlated significantly
to free TFPI (r = 0.36, P <0.001) and TF (ρ = 0.25, P =
0.002), whereas no correlation was found between free
TFPI and TF. No significant correlation between protein
levels (in plasma) and mRNA expression (in tumors) was
found for TFPI or TF.
Association between SNPs in TFPI and TF and breast
cancer subtypes
Next, we evaluated if TFPI or TF SNPs (Additional file 2:
Table S2) were associated with any clinicopathological
characteristics and molecular tumor subtypes. Four TFPI
SNPs (rs8176541, rs3213739, rs8176479, and rs2192824)
were associated with triple-negative status (Table 3) aswell as ER status and HR status (data not shown).
Strong pairwise LD existed (Additional file 3: Figure S1),
and conditional association analysis supported SNP de-
pendency (data not shown). Haplotype-based analysis
showed that the common G-G-C-T haplotype (fre-
quency 0.41) formed by the four SNPs (rs8176541-
rs3213739-rs8176479-rs2192824) showed an OR of 2.4
(P = 0.004) in triple-negative patients (Table 3).
The G-C-T-C haplotype (frequency 0.42) formed by the
four SNPs (rs3213739-rs8176479-rs2192824-rs10187622)
was associated with the basal tumor subtype with OR 2.3
(P = 0.011) (Table 3). The three-SNP haplotype T-G-T
(rs16829086-rs10179730-rs10187622) was associated with
the luminal B subtype (OR 3.5, P = 0.005, frequency 0.09),
and rs5940 was associated with the normal-like subtype
(OR 22.2, P = 0.0002). No associations between TFPI
SNPs and tumor grade, PR-status, HER2 status, the
HER2-enriched subtype or the luminal A subtype were
observed. TF SNPs did not associate with any of the clini-
copathological characteristics or molecular tumor sub-
types herein evaluated (data not shown). Age did not
correlate to any of the SNP genotypes and adjusting for
age did not affect the associations (data not shown).
Associations between SNPs and TFPI and TF expression
Further, we aimed to explore whether the TFPI or the
TF SNPs had any transcriptional or translational regula-
tory effects on the TFPI or TF mRNA expression in the
Figure 1 Tissue factor pathway inhibitor (TFPI) and tissue factor (TF) mRNA expression across molecular breast cancer subtypes. Box
and whisker plot showing the distribution of log2-transformed total TFPI (α + β), TFPIα, and TFPIβ (A), and TF tumor mRNA expression (B) across the
following intrinsic molecular subtypes of 150 of the 152 breast cancer patients; basal (n = 25), human epidermal growth factor 2 (HER2)-enriched
(n = 15), luminal A (n = 63), luminal B (n = 39) and normal-like (n = 8). P-values for multi-group comparison are indicated.
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spectively. A total of six intronic TFPI SNPs correlated
to TFPIβ mRNA expression (Table 4), and accompanied
by conditional association analysis, the LD pattern be-
tween the six SNPs encouraged haplotype analysis. The
T-A-C-C-T-C haplotype (frequency 0.03), made up of
the minor alleles of the six SNPs (rs3213739-rs8176479-
rs2192824-rs12613071-rs2192825-rs7594359 correlated
positively to TFPIβ mRNA (B = 0.76, r = 0.23, P =
0.004). Among these six SNPs, three also correlated to
total TFPI (α + β) mRNA expression (rs2192824-
rs12613071-rs7594359) with an inverse correlation of
r = −0.22 (B = −0.25, P = 0.008) for the T-T-T haplotype
(frequency 0.40). Furthermore, the minor allele T-T haplo-
type formed by two of these SNPs (rs2192824-rs7594359)correlated inversely to TFPIα mRNA expression with
r = −0.23 (B = −0.29, P = 0.004). No significant correlation
between TF SNPs and TF mRNA expression was observed
(P >0.05, data not shown).
Eight TFPI SNPs were found to be correlated to total
TFPI protein levels in patient plasma (Table 5). The A-T-
A-C-T-A-C-G haplotype composed of these eight SNPs
(rs8176541-rs3213739-rs8176479-rs2192824-rs2192825-
rs16829088-rs7594359-rs10153820) represented a com-
mon haplotype (frequency 0.19) with quite strong
correlation to total TFPI protein; r = 0.481 (B = 14.62,
P = 6.35 × 10−10). No correlation between TFPI SNPs and
free TFPI protein, or between TF SNPs and TF protein in
plasma was observed (P >0.05, data not shown). Adjusting
for age had no effect on the correlation (data not shown).
Figure 2 Tissue factor pathway inhibitor (TFPI) and tissue factor (TF) plasma levels across molecular breast cancer subtypes. Box and
whisker plot showing the distribution of plasma levels of total TFPI and free TFPI (A) and TF (B) across the following intrinsic molecular subtypes
of 148 of the 152 breast cancer patients; basal (n = 24), human epidermal growth factor 2 (HER2) HER2-enriched (n = 15), luminal A (n = 62),
luminal B (n = 39) and normal-like (n = 8). P-values for multi-group comparison are indicated.
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Survival data were not available for our patient cohort,
however, access to a merged breast cancer dataset from
GOBO allowed us to investigate possible associations
between TFPI or TF gene expression and outcome. Low
expression of total TFPI (α + β) showed significant asso-
ciation with decreased overall survival when considering
all breast cancer subtypes together (all tumors) (P = 0.015),
and the effect was even more profound in the high-
proliferative poor outcome classes; HER2-enriched (P =
0.004) and lymph node-positive cancers (P = 8*10−5)(Figure 3A). A survival effect was also observed for
normal-like tumors (P = 0.040). Similarly, low expression
of TFPIα and TFPIβ were predictive of reduced overall
survival in all tumors (P = 0.007 and 0.005), lymph node-
positive (P = 0.006 and 0.034), grade-2 (P = 0.008 and
0.001), ER-positive (P = 0.022 and 0.0007), and HER2-
enriched tumors (P = 0.097 (not significant) and 0.007)
(Figure 3B and C). Similar patterns were observed for
relapse-free survival (Additional file 8: Figure S5). Fur-
thermore, multivariate hazard ratio analysis of all tumors,
showed that tumor size and lymph node status were
Table 3 Significant association between TFPI single nucleotide polymorphisms (SNPs) and clinicopathological
characteristics and molecular subtypes
Characteristic SNP Risk allele Odds ratio 95% CI P False discovery rate
T status
T1 Reference Reference Reference Reference
T2 to T3 rs10153820 A 3.14 1.44, 6.86 0.004 0.056
TN status (ER-/PR-/HER2-negative)
No Reference Reference Reference Reference
Yes rs8176541a G 2.62 1.11, 5.35 0.026 0.092
rs3213739a G 2.58 1.34, 4.99 0.005 0.033
rs8176479a C 3.10 1.24, 7.72 0.015 0.071
rs2192824a T 2.44 1.39, 4.93 0.002 0.033
N status
Positive Reference Reference Reference Reference
Negative rs10179730 G 3.34 1.42, 7.89 0.006 0.083
Basal tumor subtype
Non-basal Reference Reference Reference Reference
Basal rs3213739a G 2.23 1.15, 4.34 0.018 0.107
rs8176479a C 2.79 1.12, 6.96 0.028 0.107
rs2192824a T 2.41 1.24, 4.65 0.009 0.107
rs10187622a C 5.20 1.17, 23.20 0.031 0.107
Luminal B tumor subtype
Non-luminal B Reference Reference Reference Reference
Luminal B rs16829086a T 2.09 1.03, 4.25 0.041 0.191
rs10179730a G 3.53 1.47, 8.46 0.005 0.066
rs10187622a T 2.73 1.24, 6.03 0.013 0.091
Normal-like tumor subtype
Non-normal-like Reference Reference Reference Reference
Normal-like rs5940 T 22.17 4.43, 110.8 0.0002 0.003
aSNPs representing a haplotype effect. SNPs are listed by ascending chromosome positions. TFPI, tissue factor pathway inhibitor; ER, estrogen receptor;
PR, progesterone receptor; HER2, human epidermal growth factor 2.
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abolished the effect of low TFPI expression (P >0.05)
(Figure 4A). This result implied that the survival effect of
TFPI expression involves lymph node metastasis and
proliferation (reflected by tumor size), thus providing a
possible explanation for why low TFPI expression had an
even greater impact to the subgroup-stratified survival
analysis, compared to analysis of all tumors (Figure 3A-C).
This was further demonstrated by multivariate analyses in
the lymph node-positive group. This covariate-adjusted
analysis showed that low total TFPI (α + β) expression
was a prognostic indicator for overall survival, independ-
ent of the strong association with tumor size (Figure 4B).
Notably, TF expression rates did not correlate with over-
all survival in all tumors (Figure 3D) or in any of the clin-
ical subgroups, nor with relapse-free survival (data not
shown).Discussion
TF and TFPI exert opposing effects in coagulation, but
also in cancer biology; although TF seems to be a tumor-
promoting factor, TFPI exerts tumor suppressor activities.
The mechanisms in which these actions take place, how-
ever, are not fully elucidated.
Here, we report several indications that TFPI have
clinical significance in breast cancer. First, mRNA ex-
pression of both total TFPI (α + β) and TFPIβ were sig-
nificantly associated with PR negativity. Our study
lacked power to detect an association with ER negativity
due to a smaller number of ER-negative (n = 35) than
PR-negative (n = 51) patients. However, PR-negativity is
a surrogate marker of a non-functioning ER pathway
[41]. There was also a tendency towards increased
mRNA expression of either total TFPI (α + β) or TFPIα
or TFPIβ in highly proliferative and poor-outcome
Table 4 Significant correlations between TFPI single nucleotide polymorphisms (SNPs) and TFPI mRNA expression in
breast tumors
Probe SNP Region Allelesa Minor allele frequency Beta r P False discovery rate
TFPIα rs2192824b Intronic C:T 0.490 −0.209 −0.180 0.029 0.200
TFPIα rs7594359b Intronic C:T 0.483 −0.219 −0.184 0.025 0.200
TFPIβ rs3213739b Intronic G:T 0.417 0.187 0.213 0.010 0.032
TFPIβ rs8176479b Intronic C:A 0.238 0.184 0.192 0.021 0.049
TFPIβ rs2192824b Intronic C:T 0.490 −0.267 −0.273 0.001 0.011
TFPIβ rs12613071b Intronic T:C 0.158 0.284 0.208 0.011 0.032
TFPIβ rs2192825b Intronic T:C 0.466 −0.251 −0.249 0.002 0.012
TFPIβ rs7594359b Intronic C:T 0.483 −0.248 −0.247 0.002 0.012
TFPIα + β rs2192824b Intronic C:T 0.490 −0.168 −0.161 0.050 0.187
TFPIα + β rs12613071b Intronic T:C 0.158 0.238 0.164 0.048 0.187
TFPIα + β rs7594359b Intronic C:T 0.483 −0.190 −0.178 0.030 0.187
aMajor:minor. bSNPs representing a haplotype effect. mRNA expression was assayed by the Agilent Human V2 Gene Expression 8x60k array, and probes for tissue
factor pathway inhibitor (TFPI)α, TFPIβ and total TFPI (TFPIα + β) mRNA were analyzed. Alleles for the positive DNA strand (UCSC annotated) are shown, and SNPs
are listed by ascending chromosome positions.
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positivity, in keeping with the survival analysis discussed
later. In accordance with the IHC determination of
HER2 status, enhanced TFPI expression was evident also
in the HER2-enriched molecular subgroup (in the
merged dataset). Moreover, TFPI expression tended to
be increased in tumors of patients with lymph node me-
tastases, supporting the results and the proposal of
Sierko et al. that TFPI localized in regional lymph nodes
may indicate a role for TFPI in lymphatic spread [9].
Additionally, tumor-expressed TFPI and TF were posi-
tively correlated, which is in line with our previous find-
ings in breast cancer cell lines that TFPI expression
follows TF expression and the aggressive basal-like
tumor subtype [7]. Stavik et al. proposed a role for TFPI
in cancer progression as they showed that overexpres-
sion of TFPIα or TFPIβ in breast cancer cell lines af-
fected expression of genes involved in cancer-related
cellular functions (for example, proliferation, migration,
and invasion). Additionally, they revealed that the geneTable 5 Significant correlations between TFPI single nucleotid
plasma
Protein SNP Region Allelesa Minor allele fre
Total TFPI rs8176541b Intronic G:A 0.283
Total TFPI rs3213739b Intronic G:T 0.417
Total TFPI rs8176479b Intronic C:A 0.238
Total TFPI rs2192824b Intronic C:T 0.490
Total TFPI rs2192825b Intronic T:C 0.466
Total TFPI rs16829088b Intronic G:A 0.250
Total TFPI rs7594359b Intronic C:T 0.483
Total TFPI rs10153820b Near 5UTR G:A 0.125
aMajor:minor. bSNPs representing a haplotype effect for total tissue factor pathway
shown.signatures following overexpression of either TFPI isoform
were associated with tumor grade and ER status, and that
TFPIα expression correlated with tumor size [42].
Taken together, we hypothesize that TFPI is a marker
of more aggressive tumors while at the same time being
a tumor suppressor. Paradoxical as it may seem, these
two hypotheses are not mutually exclusive. This is be-
cause TFPI has previously been recognized as a tumor
suppressor in experimental studies [16-21], and because
higher TFPI expression in tumors was associated with
increased survival in the present study. TFPI expression
in tumors may then serve to oppose and protect against
tumor progression. TFPI may therefore represent a
prognostic marker, but also an anti-cancer candidate
with potential for being translated into the clinic.
Contrasting the observations we made in tumors, the
plasma levels of total TFPI tended to be lower in larger
tumors, triple-negative tumors, and grade-3 tumors.
These results comply with the lack of correlation be-
tween TFPI tumor expression and TFPI plasma levels,e polymorphisms (SNPs) and total TFPI protein levels in
quency Beta r P False discovery rate
15.64 0.571 7.69 × 10−14 1.08 × 10−12
11.35 0.488 5.38 × 10−10 3.77 × 10−9
12.22 0.480 1.20 × 10−9 5.62 × 10−9
−9.88 −0.404 3.81 × 10−7 1.07 × 106
−7.55 −0.301 2.40 × 10−4 5.30 × 10−4
11.23 0.424 1.00 × 10−7 3.51 × 10−7
−6.90 −0.275 6.90 × 10−4 0.001
−7.79 −0.215 0.009 0.016
inhibitor (TFPI). Alleles for the positive DNA strand (UCSC annotated) are
Figure 3 Overall survival in breast cancer patients stratified by tissue factor pathway inhibitor (TFPI) and tissue factor (TF) expression
in tumors. Kaplan-Meier survival curve with overall survival (OS) with 10-year censoring as endpoint, stratified according to high (above the
median) and low (below median) total TFPI (α + β) gene expression levels (A), TFPIαa gene expression levels (B), TFPIβ gene expression levels
(C), and TF gene expression levels (D), in all tumors and selected clinical subgroups in which survival data were available. Analyses were performed
using the Gene expression based Outcome for Breast cancer Online (GOBO) database, and the log-rank test was used to calculate P-values. aFor TFPIα
expression results were obtained by merging the two available probe sets, as specified in Additional file 4: Table S3.
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TFPI were not influenced by or derived from the tumor
cells and thereby cannot predict plasma levels of TFPI.
Yet, no directly comparable data are available, but Lindahl
et al. reported that TFPI activity in plasma increased in
parallel with gastrointestinal cancer progression [43].Although we measured levels of TFPI instead of activity,
this suggests that the behavior of plasma TFPI proceeds
differently in different cancers. Later, Iversen et al. re-
ported that the median TFPI activity levels were within
the normal range in breast cancer. These authors also ob-
served that TFPI activity was higher in metastatic cancer
Figure 4 Multivariate survival analysis in breast cancer patients stratified by tissue factor pathway inhibitor (TFPI) and tissue factor
(TF) expression in tumors. Multivariate survival analysis derived from the Gene expression based Outcome for Breast cancer Online (GOBO)
database of (A) total TFPI (α + β), TFPIα, and TFPIβ tumor expression in all tumors, and (B) total TFPI (α + β) tumor expression in the lymph
node-positive group. Tumor size, age, histological tumor grade, lymph node statusa and estrogen receptor (ER) status were included as covariates.
Hazard ratios, 95% CIs and corresponding P-values are specified for each covariate. aOmitted from the analysis of the lymph node-positive group.
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oped distant metastases at the time of inclusion.
The complexity of the different forms of circulating
TFPI (that is, full-length TFPI, C-terminal truncated,
and lipid-bound) [15] was illustrated, as free TFPI, un-
like total TFPI, could not be designated as having any
clinical relevance. In line with this, no differences in free
TFPI plasma levels were detected between breast cancer
patients and controls in our preceding study [45].
We identified several TFPI SNPs (with haplotype effects)
that were more frequent in specific clinicopathological
tumor characteristics, such as tumor size, triple-negative
status and lymph node status, as well as basal and luminalB tumor subtypes. Although the precise role for these
SNP associations is still to be elucidated, this study
pinpoints the importance of focusing on breast cancer
heterogeneity, as in a recent study we found that the
frequencies of TFPI SNPs in a group of breast cancer
patients with all subtypes combined (n = 366), were no
different from healthy control subjects [45]. Some of the
SNPs that followed distinct clinical groups (rs3213739,
rs8176479, rs2192824, rs8176541 and rs10153820) also
correlated with total TFPI (α + β), TFPIα or TFPIβ tumor
mRNA expression, or total TFPI plasma levels. Certain
SNPs with a regulatory effect on total TFPI plasma levels
also associated with triple-negative status (rs8176541,
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(rs10153820), thereby providing a possible mechanistic ra-
tionale for why total TFPI levels were decreased in pa-
tients with triple-negative and larger tumors. However,
the exact mechanism(s) by which these SNPs regulate
TFPI protein levels demand experimental verification.
Most SNPs in this study were positioned in introns, but
many of them were in strong LD with SNPs located in 3′
UTR and 5′ UTR (not shown), which are regions known
to have potential influence on gene expression.
The minor allele of rs10153820 (−399C/T) was associ-
ated with decreased total TFPI plasma levels, and the
minor allele of rs8176541, a perfect predictor of rs8176592
(−33 T/C) (pairwise LD r2 = 1.00), correlated to higher
total TFPI plasma levels. This result is in line with another
study that genotyped rs8176592 [46], whilst another study
failed to show an effect of this SNP on total TFPI plasma
levels [29].
In light of the abundant TF expression in cancers
[6-8,10] and involvement in angiogenesis, metastasis and
tumor growth [11-14], the virtual absence of clinical sig-
nificance of TF tumor mRNA expression or plasma
levels, or TF genetic polymorphisms was not anticipated,
that is, with the exception of a reverse association be-
tween TF mRNA tumor expression and tumor grade.
This result is in conflict with Kocatürk et al. who found
positive correlation between TF and grade [6], but in
agreement with the merged GOBO breast cancer dataset
in this study. We could hypothesize that tumor ex-
pressed TF may be more important in the earlier phases
of malignant transformation, as suggested in pancreatic
cancer [47].
In contrast to the experimental evidence that points to
TF as an important contributor in tumor progression,
studies investigating the clinical relevance of tissue factor
in breast cancer patients have generated less conclusive
results. Adding to the hypothesis that a procoagulant state
extends beyond the risk of venous thromobosis (VT),
Hernández et al. reported that increased TF plasma levels
and activity in a number of cancers, amongst them breast
cancer, was indicative of worse prognosis, but not of VT
[48]. Also Ueno et al. demonstrated that TF plasma levels
were elevated in breast cancer patients compared to con-
trols. However, neither TF plasma levels nor tumor ex-
pression were found related to clinical stage, HR status or
lymph-node metastasis [8]. Yet another study failed to de-
tect any correlation between breast tumor-expressed TF
and HR status, node status, grade or tumor size [10].
Kocatürk et al., found that both flTF and alternatively
spliced TF (asTF) [GenBank:NM_001178096] were asso-
ciated with increasing tumor grade, while asTF was also
associated with increasing breast tumor size [6], suggest-
ing that the clinical significance of asTF is at least as im-
portant as that of flTF. Consequently, future studiesaddressing TF in relation to cancer should include the
different forms of TF (that is, asTF and flTF [6,49], cryp-
tic versus active TF [50], and phosphorylated TF [10]).
Also noteworthy; methodological discrepancies in meas-
uring TF may to some extent account for the conflicting
results among studies addressing TF in cancer (for ex-
ample, mRNA versus protein and use of different TF de-
tection antibodies).
In clinical cancer research, death is a common end-
point of interest. Because survival data were not avail-
able for the patients included in our study, we made use
of a merged clinical dataset to investigate the effect of
TFPI and TF tumor expression on survival among breast
cancer patients. No difference in overall or relapse-free
survival was observed between patients with high or low
levels of TF. This is somehow contradictory to the study
of Ueno et al. who found that breast cancer patients
with TF-positive tumors were associated with reduced
overall survival, however, not with disease-free survival
[8]. On the contrary, no previous studies have described
survival data directly in relation to tumor expressed
TFPI, but Stavik et al. reported that the gene expression
signature resulting from TFPIβ overexpression corre-
lated with relapse-free survival in breast cancer [42]. We
now report that breast cancer patients with low tumor
expression of both isoforms of TFPI had worse outcome
in terms of both overall- and relapse free survival com-
pared to patients with higher TFPI expression. There-
fore, it seems that increased tumor expression of TFPI
may be beneficial in breast cancer.Conclusions
Here we provide results suggesting that TFPI represents
a promising marker of breast cancer progression and
prognosis. This was especially evident in clinically rele-
vant groups such as lymph node-positive patients. The
clinical relevance of expression and genetic variants of
TFPI in breast cancer appeared distinct from that of TF.
Together with the previously demonstrated tumor sup-
pressor effects of TFPI, the beneficial survival effect of
tumor-expressed TFPI highlights the potential of TFPI
as a candidate in cancer therapy, and this clearly de-
serves further investigation for possible translation to
clinical practice.Additional files
Additional file 1: Table S1. Probes from the Agilent Human V2 Gene
Expression 8x60k array in which results were used in the study. SNPs
occurring in probes are shown in bold.
Additional file 2: Table S2. All analyzed single nucleotide polymorphisms
(SNPs) in tissue factor pathway inhibitor (TFPI) and tissue factor (TF) genes.
Alleles for the positive strand are shown (UCSC-annotated).
Tinholt et al. Breast Cancer Research  (2015) 17:44 Page 14 of 15Additional file 3: Figure S1. Linkage disequilibrium (LD) map of all
fourteen TFPI SNPs included in the study. Dʹ values are shown.
Additional file 4: Table S3. Probe set regions for the Affymetrix U133A
microarray used in the study.
Additional file 5: Figure S2. Expression heatmaps for A) total TFPI
(α + β), TFPIβ and TF mRNA expression in breast tumors differentiated by
clinically relevant subgroups of PR-status (PR negative and PR positive)
and tumor grade (G1 + 2 and G3), and B) plasma levels of total TFPI
according to T-status (T1 and T2 + T3). The color key is indicated.
Additional file 6: Figure S3. Box and Whiskers plot showing the
distribution of log2 transformed total TFPI (α + β), TFPIα, and TFPIβ and
TF tumor mRNA expression across the following PAM50 subtype
signatures of 150* breast cancer patients; basal (n = 304/357), HER2
enriched (n = 240/152), luminal A (n = 465/482), luminal B (n = 471/289)
and normal-like (n = 304/257). Data were derived from the GOBO
database. P-values for ANOVA testing are indicated.
Additional file 7: Figure S4. Box and Whiskers plot showing the
distribution of TF gene expression for tumor samples across the three
classes of histological grade. Expression rates are analyzed by Affymetrix
Human Genome U133A arrays and data were derived from all tumors of
the GOBO database.
Additional file 8: Figure S5. Kaplan-Meier survival curve with relapse-
free survival (RFS) with 10-year censoring as the endpoint, stratified
according to high (above the median) and low (below median) total
tissue factor pathway inhibitor (TFPI) (α + β) gene expression levels (A),
TFPIαa gene expression levels (B), and TFPIβ gene expression levels (C), in
all tumors and selected clinical subgroups in which survival data were
available. Analyses were performed using the Gene expression based
Outcome for Breast cancer Online (GOBO) database, and the log-rank test
was used to calculate P-values. aFor TFPIα expression results were
obtained by merging the two available probe sets, as specified in
Additional file 4: Table S3.Abbrevations
asTF: alternatively spliced tissue factor; ANOVA: analysis of variance;
ELISA: enzyme-linked immunosorbent assay; FDR: false discovery rate;
GOBO: Gene expression based Outcome for Breast cancer Online;
ER: estrogen receptor; HE: hematoxylin and eosin; HER2: human epidermal
growth factor receptor 2; HR: hormone receptor; IHC: immunohistochemistry;
LD: linkage disequilibrium; MAF: minor allele frequency; OR: odds ratio;
PR: progesterone receptor; PAM50: prediction analysis of microarray 50;
SNP: single nucleotide polymorphism; TF: tissue factor; TFPI: tissue factor
pathway inhibitor; TN: triple negative; UTR: untranslated region; VT: venous
thromobosis.
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